Focus
AUTOIMMUNITÀ NEL BAMBINO
La tolleranza immunitaria: un difficile equilibrio
LUIGI D. NOTARANGELO
Clinica Pediatrica, Università di Brescia
Giugno 1999 - pagg. 357 -370
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Tauber AI: The immune self: theory or
metaphor? Immunol Today 15, 134-135, 1994.
2. Wang J, Lenardo MJ: Molecules involved in cell death and peripheral tolerance. Curr Opin Immunol 9, 818-825,1997.
3. Janeway CA Jr, Kupfer A, Viret C, et al: Tcell development, survival and signalling. The Immunologist 6, 5-12, 1998.
4. Omenn GS: Familial Reticuloendotheliosis with Eosinophilia. N Engl J Med 273, 427- 432, 1965.
5. Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, et al: Partial V(D)J Recombination Activity Leads to Omenn Syndrome. Cell 93, 885-896, 1998.
6. Hunig T, Schimpl A: Systemic autoimmune disease as a consequence of defective lymphocyte death. Curr Opin Immunol 9, 826-830, 1997.
7. Nagata S, Golstein P: The Fas Death Factor. Science 267, 449-1456, 1995.
8. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Imm Tod 16, 39-43, 1995.
9. Fisher GH, Rosenborg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, et al: Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome. Cell 81, 935- 946, 1995.
10. Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N, et al: Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 348, 719-723, 1996.
11. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, et al: Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity. Science 268, 1347-1349, 1995.12. Bettinardi A, Brugnoni D, Quiròs-Roldan E, Malagoli A, La Grutta S, Correra A, Notarangelo LD: Missense mutations in the FAS gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis. Blood 89, 902-909, 1997.
13. Vaishnaw AK, Orlinick JR, Chu J-L, et al: The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 103 (3), 355-363, 1999.
14. Dianzani U, Bragardo M, Di Franco D, Alliaudi C, Scagni P, Buonfiglio D, et al: Deficiency of the Fas Apoptosis Pathway Without Fas Gene Mutations in Pediatric Patients With Autoimmunity/Lymphoproliferation. Blood 89, 2871-2879, 1997.
15. Kondo T, Suda T, Fukuyama H, et al: Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3, 409-413, 1997.
16. French LE, Tschopp J: Thyroiditis and hepatitis: Fas on the road. Nat Med 3, 387- 388, 1997.
17. Hausmann S, Wucherpfennig KW: Activation of autoreactive T cells by peptides from human pathogens. Curr Opin Immunol 9, 831-838, 1997.
18. Groux H, O’Garra A, Bigler M, et al: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742, 1997.
19. Wegmann TG, Lin H, Guilbert L, Mosmann TR: Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 14, 353-356, 1993.
20. Seidl C, Donner H, Fischer B, et al: CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 51, 62-66, 1998.
21. Marron MP, Raffel LJ, Garchon HJ, et al: Insulin-dependent diabetes mellitus (IDDM) is associated witrh CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 8, 1275-1282, 1997.
2. Wang J, Lenardo MJ: Molecules involved in cell death and peripheral tolerance. Curr Opin Immunol 9, 818-825,1997.
3. Janeway CA Jr, Kupfer A, Viret C, et al: Tcell development, survival and signalling. The Immunologist 6, 5-12, 1998.
4. Omenn GS: Familial Reticuloendotheliosis with Eosinophilia. N Engl J Med 273, 427- 432, 1965.
5. Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, et al: Partial V(D)J Recombination Activity Leads to Omenn Syndrome. Cell 93, 885-896, 1998.
6. Hunig T, Schimpl A: Systemic autoimmune disease as a consequence of defective lymphocyte death. Curr Opin Immunol 9, 826-830, 1997.
7. Nagata S, Golstein P: The Fas Death Factor. Science 267, 449-1456, 1995.
8. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Imm Tod 16, 39-43, 1995.
9. Fisher GH, Rosenborg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, et al: Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome. Cell 81, 935- 946, 1995.
10. Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N, et al: Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 348, 719-723, 1996.
11. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, et al: Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity. Science 268, 1347-1349, 1995.12. Bettinardi A, Brugnoni D, Quiròs-Roldan E, Malagoli A, La Grutta S, Correra A, Notarangelo LD: Missense mutations in the FAS gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis. Blood 89, 902-909, 1997.
13. Vaishnaw AK, Orlinick JR, Chu J-L, et al: The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 103 (3), 355-363, 1999.
14. Dianzani U, Bragardo M, Di Franco D, Alliaudi C, Scagni P, Buonfiglio D, et al: Deficiency of the Fas Apoptosis Pathway Without Fas Gene Mutations in Pediatric Patients With Autoimmunity/Lymphoproliferation. Blood 89, 2871-2879, 1997.
15. Kondo T, Suda T, Fukuyama H, et al: Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3, 409-413, 1997.
16. French LE, Tschopp J: Thyroiditis and hepatitis: Fas on the road. Nat Med 3, 387- 388, 1997.
17. Hausmann S, Wucherpfennig KW: Activation of autoreactive T cells by peptides from human pathogens. Curr Opin Immunol 9, 831-838, 1997.
18. Groux H, O’Garra A, Bigler M, et al: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742, 1997.
19. Wegmann TG, Lin H, Guilbert L, Mosmann TR: Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 14, 353-356, 1993.
20. Seidl C, Donner H, Fischer B, et al: CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 51, 62-66, 1998.
21. Marron MP, Raffel LJ, Garchon HJ, et al: Insulin-dependent diabetes mellitus (IDDM) is associated witrh CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 8, 1275-1282, 1997.